Why Is JEM Stock Up 182% June 30 2026 | ABVX Phase 3 Data CUPR ENPH UNCY FDA Watch List

First day of Q3 and four distinctly different setups on the scanner. A 10.73M float Chinese company is up 182% on a crypto and AI executive appointment. A French biotech is up 35% after clearing a cancer signal that cut the stock in half four weeks ago. CUPR is running for the sixth session since its FDA clearance. And Unicycive is down 49% after its FDA PDUFA date passed. NKE reports after the close tonight. Here is what is on the board.

Today is Q3 Day 1. Window dressing is over. The institutional flows that pushed RKLB, MSTR, ASTS, and PLTR higher through yesterday reverse as the new quarter begins. The tape resets. The names running today need their own catalyst, not positioning flow.

The top gapper is JEM, 707 Cayman Holdings. The company appointed Robin Hoksnes Karlsen as executive director on June 30, adding real estate and digital-asset expertise as the Hong Kong-based apparel and supply-chain company pivots to explore AI-powered, blockchain-enabled technologies. 707 Cayman previously signed a memorandum of understanding with Precious Choice Global to explore building a cryptocurrency treasury reserve in Bitcoin, Binance Coin, and Ethereum. The stock is up 181.98% at $3.13 on a 10.73M float with 40.05M in volume pre-market. Volume has already exceeded the float nearly four times. The company executed a 20-for-1 share consolidation in April to maintain Nasdaq compliance, which means this is a recently restructured micro-cap Chinese company layering on a crypto and AI narrative. The move is entirely float and narrative driven.

ABVX is up 34.73% at $129.57 on a 58.86M float. Abivax, a French clinical-stage biotech, released expanded Phase 3 integrated safety data for obefazimod this morning that directly countered the cancer signal that cratered the stock on June 2. The company had released data on June 2 showing cancer cases among patients taking the highest dose of obefazimod in ulcerative colitis trials, which dropped the stock approximately 44%. Today's expanded safety database shows exposure-adjusted malignancy incidence rates falling within published ulcerative colitis background ranges. The cancer signal was not confirmed as drug-related. Abivax confirmed it remains on track to submit a New Drug Application to the FDA in Q4 2026. The 34% move today is a partial recovery of the June 2 crash, not a new breakout.

CUPR is up 20.45% at $5.36. Cuprina Holdings received FDA 510(k) clearance for MEDIFLY Maggots on June 15, ran 36.71% on June 24 in the first scanner appearance, and is now continuing to new highs six sessions after the FDA catalyst. We covered CUPR in the June 24 watch list. First-in-class FDA clearances in wound care have historically produced multi-week sustained moves. At 7.37M float and 5.55M in pre-market volume, volume has already exceeded the float before the open.

ENPH is up 16.93% at $56.50. Enphase Energy received a Barclays upgrade on June 18 from Underweight to Equal Weight with a price target raised to $51 from $30, citing the company's positioning in AI data center power via its solid-state transformer business, a segment analysts estimate addresses a $2 billion annual U.S. market by the late 2020s. The stock also launched its IQ9N microinverter for residential use in late June. At $56.50 today the stock is above Barclays' $51 target, but the AI data center narrative is pulling additional analyst attention.

UNCY is down 49.21% at $3.91. Unicycive Therapeutics had a PDUFA target action date of June 29, 2026 for its oxylanthanum carbonate NDA resubmission. OLC targets hyperphosphatemia in chronic kidney disease patients on dialysis. The prior complete response letter was related to a third-party cGMP manufacturing issue rather than clinical or safety concerns. The 49% crash this morning confirms the FDA did not approve the resubmission by the PDUFA date. No official FDA decision statement was confirmed on the wire before market open. A second complete response letter or approval request extension would explain the magnitude of the selloff.

707 Cayman Holdings is a Hong Kong-based company that began as an apparel and supply-chain business and has been pivoting toward AI and digital assets. Today's executive appointment adds a director with real estate and digital-asset expertise to accelerate the pivot. The company has a memorandum of understanding to explore a crypto treasury reserve in Bitcoin, Binance Coin, and Ethereum. It executed a 20-for-1 share consolidation in April to maintain Nasdaq compliance, which means the stock was recently trading below $1 before the consolidation. At $3.13 this morning on 40.05M in pre-market volume against a 10.73M float, the float has turned over nearly four times. This is a narrative squeeze on a recently restructured Chinese micro-cap with no revenue confirmation tied to the crypto and AI pivot. Pure float dynamics.

Abivax released expanded Phase 3 integrated safety data for obefazimod showing that exposure-adjusted malignancy rates fall within published background ranges for ulcerative colitis patients. This directly counters the June 2 cancer signal data that dropped the stock 44%. Obefazimod targets refractory ulcerative colitis patients who have not responded to standard therapies. The company confirmed an FDA NDA submission on track for Q4 2026. At $129.57 today the stock is recovering from the June 2 crash low but has not reclaimed its pre-crash level. This is a safety data reversal, not a new clinical milestone. The move is logical but the NDA submission and FDA review timeline remain the next catalysts.

CUPR was first covered in the June 24 watch list at +36.71% on FDA 510(k) clearance for MEDIFLY Maggots, the first U.S. clearance for a Lucilia cuprina maggot debridement product. Today is the sixth session since that coverage and the stock is continuing higher. At 5.55M in pre-market volume on a 7.37M float, the float has nearly turned over before the open. First-in-class FDA clearances in niche wound care categories have produced multi-week sustained moves historically because there is a real business story anchoring the momentum rather than a one-day press release. Cuprina also had Nasdaq compliance resolved in mid-June. Stacked catalysts with a small float is the sustained-mover setup.

Enphase is running on the Barclays upgrade from June 18 and a new AI data center narrative. Barclays raised from Underweight to Equal Weight with a $51 price target from $30, citing Enphase's solid-state transformer technology as a credible entry point into the data center power market with approximately $2 billion in annual U.S. addressable market. The IQ9N microinverter residential launch also hit in late June. At $56.50 today the stock is trading above Barclays' $51 target. The persistent headwinds remain: declining solar demand, tariff impacts, and reduced homeowner incentives have driven a projected 30% earnings decline this year. The AI data center narrative is the new story. The fundamental business is still under pressure.

Unicycive had a June 29, 2026 PDUFA target action date for its oxylanthanum carbonate NDA resubmission, targeting hyperphosphatemia in chronic kidney disease patients on dialysis. The prior complete response letter from the FDA was related to a third-party manufacturing cGMP issue rather than clinical or safety data concerns. The company had $54.9M in cash as of year-end 2025 and H.C. Wainwright had reiterated a Buy rating ahead of the decision. The 49% crash confirms the FDA did not approve. A second complete response letter for manufacturing or labeling would keep the approval path open but delay it 6-12 months minimum. Watch for the official FDA response statement to determine whether this is a fixable manufacturing issue or a clinical rejection.

Disclosure: I am not a registered financial advisor. This is educational content on market news, economic calendar, and historical trade reviews. Trading involves risk of loss. Past performance does not guarantee future results. Nothing herein is a recommendation to buy or sell any security. Assume I have positions in tickers discussed. Do not make financial decisions based solely on this content. Trade your own decisions.